Advances in the development of Direct-Acting Antivirals (DAAs), particularly pangenotypic drugs, have led to a high rate of hepatitis C virus (HCV) eradication. Notably, real- world studies have confirmed the efficacy and safety of pangenotypic DAA combinations reported in registration trials. The aim of this study was to review the treatment recommendations, and the efficacy and safety data of anti-HCV pangenotypic drugs reported in registration clinical trials and in recent real-life cohort studies.
Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection / Scotto, R.; Buonomo, A. R.; Moriello, N. S.; Maraolo, A. E.; Zappulo, E.; Pinchera, B.; Gentile, I.; Borgia, G.. - In: REVIEWS ON RECENT CLINICAL TRIALS. - ISSN 1574-8871. - 14:3(2019), pp. 173-182. [10.2174/1574887114666190306154650]
Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection
Scotto R.;Buonomo A. R.;Maraolo A. E.;Zappulo E.;Pinchera B.;Gentile I.;Borgia G.
2019
Abstract
Advances in the development of Direct-Acting Antivirals (DAAs), particularly pangenotypic drugs, have led to a high rate of hepatitis C virus (HCV) eradication. Notably, real- world studies have confirmed the efficacy and safety of pangenotypic DAA combinations reported in registration trials. The aim of this study was to review the treatment recommendations, and the efficacy and safety data of anti-HCV pangenotypic drugs reported in registration clinical trials and in recent real-life cohort studies.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
